Brief: Mauna Kea Technologies Receives U.S. FDA Clearance Of Its Next-Generation Cellvizio® Platform
Aug 24 (Reuters) - Mauna Kea Technologies SAS MKEA.PA :
* MAUNA KEA TECHNOLOGIES RECEIVES U.S. FDA 510(K) CLEARANCE
OF ITS
NEXT-GENERATION CELLVIZIO® PLATFORM COMBINED WITH A FLUORESCENT
CONTRAST AGENT
* NEXT-GENERATION CELLVIZIO® PLATFORM IS NOW CLEARED FOR USE
WITH
FLUORESCEIN DYE TO IMAGE BLOOD FLOW IN MICROVASCULATURE AND
CAPILLARIES AS A COMBINATION DRUG-DEVICE
Source text for Eikon: ID:nBw8xMvxQa
Further company coverage: MKEA.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Mauna Kea Technologies SA
See all newsBrief: Mauna Kea Technologies Confirms Trajectory Toward Profitability By Year-End 2027
Brief: Mauna Kea Technologies Announces Results Of Its Combined General Meeting
French and Benelux stocks-Factors to watch 21 Nov
Brief: Mauna Kea Technologies Receives NMPA Regulatory Approval In China For Its Next-Generation Cellvizio Platform
Europe Research Roundup: Craneware, Croda, Genus